Vertex Pharmaceuticals Incorporated
NASDAQ:VRTXBiotechnology
-$6.43 today
- Market cap
- $136.01B
- Beta
- 0.31
- P/E (TTM)
- 26.5
- EPS (TTM)
- $17.07
Volume 1.29M
Average 1.26M
VRTX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Vertex Pharmaceuticals IncorporatedNASDAQ: VRTX
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development growth accelerates
Q3 FY2026 research & development of $1.32B rose 27.9% year over year, ahead of the +6.5% change in trailing-twelve-month research & development. Sequentially, it rose 32.9% from the prior quarter. Over 3 fiscal years it compounded at +12.2% a year.
Context
- Research & development amounted to 31.1% of revenue in FY2025, down 1.9 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +27.9% holds above the trailing-twelve-month pace of +6.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 3.75B USD
- Year-over-year change
- +3.4%
- 4-year CAGR
- +5.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.75B | +3.4% |
| FY2024 | 2024-12-31 | 3.63B | +14.8% |
| FY2023 | 2023-12-31 | 3.16B | +19.1% |
| FY2022 | 2022-12-31 | 2.66B | -13.0% |
| FY2021 | 2021-12-31 | 3.05B | — |
Research & Development vs competitors
How VRTX compares with its peers on the latest reported figures
- VRTX's LTM Sep 2026 research & development of $4.25B is the 2nd highest of the 11 companies compared; the peer median is $650.95M.
- Its year-over-year change of +6.5% is the 5th highest of 11, against a peer median of +3.9%.
- Research & development amounts to 32.7% of revenue for VRTX, versus a peer median of 85.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $181.1B | +19955.1% | +12.4% | 17.6% | |
| LTM Sep 2026 | $4.25B | +6.5% | +12.2% | 32.7% | |
| LTM Jun 2026 | $1.51B | +30.1% | +14.5% | 31.4% | |
| LTM Sep 2026 | $923.16M | +4.7% | +3.2% | 96.2% | |
| LTM Mar 2026 | $902.58M | -34.5% | +20.2% | 41.3% | |
| LTM Mar 2026 | $770.95M | +12.5% | +2.0% | 115.2% | |
| LTM Jun 2026 | $530.96M | +12.1% | +6.1% | 74.5% | |
| LTM Jun 2026 | $433.31M | -14.7% | -11.3% | 43.0% | |
| LTM Jun 2026 | $408.66M | +3.1% | +9.5% | 261.9% | |
| LTM Mar 2026 | $361.17M | -21.5% | -2.5% | 546.5% | |
| LTM Sep 2026 | $283.28M | +1.6% | -16.9% | 1125.4% | |
| Peer median (excluding VRTX) | $650.95M | +3.9% | +4.7% | 85.3% | |
Competitors are the stored peer set for VRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 7.57B | 8.93B | 9.87B | 11.02B | 12.07B |
| Cost of Revenue | 904.2M | 1.08B | 1.26B | 1.53B | 1.81B |
| Gross Profit | 6.67B | 7.85B | 8.61B | 9.49B | 10.27B |
| Gross Margin | 88.1% | 87.9% | 87.2% | 86.1% | 85.0% |
| Research & Development | 3.05B | 2.66B | 3.16B | 3.63B | 3.75B |
| Selling, General & Admin | 840.1M | 944.7M | 1.14B | 1.46B | 1.75B |
| Operating Expenses | 3.89B | 3.54B | 4.78B | 9.72B | 5.51B |
| Depreciation & Amortization | 125.6M | 148.3M | 181.3M | 207.2M | 209.8M |
| EBITDA | 2.92B | 4.44B | 4.61B | 486.3M | 4.87B |
| EBITDA Margin | 38.5% | 49.7% | 46.7% | 4.4% | 40.3% |
| Operating Income | 2.78B | 4.31B | 3.83B | (232.9M) | 4.76B |
| Operating Margin | 36.7% | 48.2% | 38.8% | -2.1% | 39.4% |
| Interest Income | 4.9M | 144.6M | 614.7M | 598.1M | 490.9M |
| Interest Expense | 61.5M | 54.8M | 44.1M | 30.6M | 13.3M |
| Other Income / Expenses | (51.7M) | (75M) | 547.8M | 481.4M | (117.5M) |
| Income Before Tax | 2.73B | 4.23B | 4.38B | 248.5M | 4.64B |
| Pre-Tax Margin | 36.0% | 47.4% | 44.4% | 2.3% | 38.5% |
| Income Tax Expense | 388.3M | 910.4M | 760.2M | 784.1M | 690M |
| Net Income | 2.34B | 3.32B | 3.62B | (535.6M) | 3.95B |
| Net Margin | 30.9% | 37.2% | 36.7% | -4.9% | 32.7% |
| EPS (Basic) | 9.09 | 12.97 | 14.05 | (2.08) | 15.46 |
| EPS (Diluted) | 9.01 | 12.82 | 13.89 | (2.08) | 15.32 |
| Weighted Avg Shares | 257.7M | 256.1M | 257.7M | 257.5M | 255.7M |
| Weighted Avg Shares (Diluted) | 259.9M | 259.1M | 260.5M | 257.9M | 258M |
Vertex Pharmaceuticals Incorporated
NASDAQ:VRTX
Intrinsic Alpha fair value
Locked
Current Price
$536.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.